



CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR 1.10)

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

By: Lewis J. Kreisler
Lewis J. Kreisler

Date: 2/5/04

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Atkins, et al.	Atty. Ref.:	18013-C1
Appl. No.:	10/717,101	Group Art Unit:	1648
Filed:	November 19, 2003	Examiner:	Bao Q. Li
For:	PURGING OF CELLS USING VIRUSES		

* * * * *

February 5, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO-1449. A copy of each listed document is enclosed.

This Communication is being filed within three months of the filing date or before the mailing of a first Office Action on the merits. Consideration of this Statement is respectfully requested.

Inventor(s): Atkins, et al.
Application No.: 10/717,101
Page 2


It is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,

A handwritten signature in cursive script, reading "Lewis J. Kreisler".

Lewis J. Kreisler
Reg. No. 38522
Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794



Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/717,101
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 19, 2003
		First Named Inventor	Harold L. Atkins
		Group Art Unit	1648
		Examiner Name	Bao Q. Li
		Attorney Docket Number	18013-C1
Sheet	2	of	3


NON PATENT PUBLICATIONS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Stuart, "Autologous Bone Marrow Transplantation for Leukemia", Seminars in Oncology, Vol. 20, No.5, Suppl 6, pages 40-54, October 1993.	
		Hammert, et al., "Purging marrow or peripheral blood stem cells for autografting", Current Opinion in Hematology, Vol. 4, pages 423-428, 1997.	
		Schneidkraut, et al., "The Contribution of Animal Models to the Development of Treatments for Hematologic Revcovery Following Myeloablative Therapy: A Review", Journal of Hematotherapy, Vol. 5, pages 631-646, 1996.	
		Rummel, et al., "Future Paradigm for Autologous Bone Marrow Transplantation: Tumor Purging and Ex Vivo Production of Normal Stem and Progenitor Cells", Journal of Hematotherapy, Vol. 3, pages 213-218, 1994.	
		Kvalheim, et al., "Purging of Tumor Cells from Leukapheresis Products: Experimental and Clinical Aspects", Journal of Hematotherapy, Vol. 5, pages 427-436, 1996.	
		Bird, et al., "4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement", Bone Marrow Transplantation Vol. 18, pages 309-313, 1996.	
		Hammert, et al., "Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia", Blood Reviews, Vol. 11, pages 80-90, 1997.	
		Villeneuve, "Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasia with rhodamine derivatives", Biotechnol. Appl. Biochem., Vol. 30, pages 1-17, 1999.	
		Hirai, et al., "Adenovirus p53 Purging for Human Breast Cancer Stem Cell Products", Acta Haematol, Vol. 101, pages 97-105, 1999.	
		Marini, et al. "Purging of Contaminating Breast Cancer Cells from Hematopoietic Stem Cell Grafts by Adenoviral GAL-TEK Gene Therapy and Magnetic Antibody Cell Separation", Clinical Cancer Research, Vol. 5, pages 1557-1568, June 1999.	
		Damon, et al., "Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment of containing mitoxantrone for acute myelogenous leukemia", Bone Marrow Transplantation, Vol. 17, pages 93-99, 1996.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.